• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    Satellos Files IND for Ph 2 Trial of SAT-3247 in DMD Patients

    BUSINESSWIRE

    Satellos Q2 2025 Results and Upcoming Clinical Milestones

    BUSINESSWIRE

    Satellos to Speak at Canaccord Genuity`s 45th Growth Conference

    BUSINESSWIRE

    Satellos Unveils Promising Phase 1b Data for DMD Drug SAT-3247

    BUSINESSWIRE

    Satellos to Present at CureDuchenne Futures National Conference

    BUSINESSWIRE

    Satellos to Present at Healthcare Investor Conference

    BUSINESSWIRE

    Satellos to Participate in Two April Investor Conferences

    BUSINESSWIRE

    Satellos Reports 2024 Financial Results and Highlights Progress

    BUSINESSWIRE

    Satellos to Present at Oppenheimer Annual Healthcare Conference

    BUSINESSWIRE

    Satellos Announces Overnight Offering of Common Shares

    BUSINESSWIRE

    Satellos to Join Duchenne KOL Investor Webinar on Dec. 4, 2024

    BUSINESSWIRE

    Satellos Reports Q3 2024 Financial Results & Clinical Update

    BUSINESSWIRE

    Satellos Submits Regulatory Filing For Phase 1 Trial Of SAT-3247

    BUSINESSWIRE

    Satellos Presents Preliminary DMD Treatment Data For SAT-3247

    BUSINESSWIRE

    Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD)

    BUSINESSWIRE

    Satellos: Advisory Board For Duchenne Muscular Dystrophy Drug Candidate

    BUSINESSWIRE

    Satellos Announces Q1 2024 Results, Operational Highlights

    BUSINESSWIRE

    Satellos Bioscience Announces Shareholder Meeting Results

    BUSINESSWIRE

    Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024

    BUSINESSWIRE

    Satellos Recognized as a Top 50 TSX Venture Exchange Company

    BUSINESSWIRE

    Satellos to Commence Trading on the Toronto Stock Exchange

    BUSINESSWIRE

    Satellos Announces Preliminary Data in Facioscapulohumeral Muscular Dystrophy

    BUSINESSWIRE

    Satellos Announces Management Team Update

    BUSINESSWIRE

    Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.